A placebo-controlled trial has shown that a single dose of psilocybin, the active ingredient in magic mushrooms, leads to rapid and lasting reductions in obsessive-compulsive disorder symptoms among treatment-resistant patients. The effects persisted for at least 12 weeks in participants who had not responded to conventional therapies. Researchers highlight the potential of this psychedelic for mental health treatment, though larger studies are needed.

이 웹사이트는 쿠키를 사용합니다

사이트를 개선하기 위해 분석을 위한 쿠키를 사용합니다. 자세한 내용은 개인정보 보호 정책을 읽으세요.
거부